Phase Ib Dose-Ranging Study of the Safety, PK, PD & Efficacy of the Activin Signaling Inhibitor HS235 vs placebo added to background therapy in PAH (SEASIDE)

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-523010-89-00

Acronym

HS235-002

Enrollment

Registered

2025-12-23

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary arterial hypertension

None listed

Sex/Gender

All

Age

18 Years to No maximum

Hungary, Poland, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026